Sanos Bioscience

Sanos Bioscience focuses on developing innovative biomedical solutions aimed at enhancing patient outcomes through advanced technology and clinical practices. Their work primarily targets osteoarthritis treatment and research. Sanos Bioscience, established in 2003, operates from Herlew, Denmark. The company specializes in biomedical technologies and was fully acquired by Investcorp and its management in December 2020, marking a strategic pivot to deepen its engagement in osteoarthritis research.

The total amount raised by the company, primarily through its latest BUYOUT funding round in December 2020, is DKK 60. 000 mn, backed by investors SEB Asset Management and SLS Invest. The founder's details are not specified. Sanos Bioscience specializes in delivering advanced biomedical solutions aimed at improving treatment efficiency for osteoarthritis.

Their primary offerings include a software platform integrating analytics and machine learning designed specifically for clinical applications. This platform enhances decision-making processes in healthcare settings, addressing the needs of both small and mid-sized enterprises in the healthcare sector, with a growing focus on expanding their customer base across North America and Europe. The company's revenue model is structured around a subscription-based access to its software platform, allowing clients to choose plans that best fit their operational needs. This model includes tiered pricing options, ensuring accessibility for businesses of varying sizes while fostering lasting partnerships with clients.

In the most recent year, 2023, Sanos Bioscience reported an EBITDA of DKK 2,440,960. 10. Sanos Bioscience's future growth strategy is anchored in expanding its research clinics network and enhancing its product offerings for osteoarthritis treatment. The acquisition completed in December 2020 is expected to support these initiatives by increasing market penetration.

The company is targeting expansion into additional European markets over the next two years, leveraging recent funding to bolster its research capabilities and introduce new products designed for clinical applications.